Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37
Lintao Qu, Michael J. Caterina
Lintao Qu, Michael J. Caterina
Published July 16, 2018
Citation Information: J Clin Invest. 2018;128(8):3246-3249. https://doi.org/10.1172/JCI122203.
View: Text | PDF
Commentary

Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37

  • Text
  • PDF
Abstract

Resolution of inflammation is a critical process that is facilitated by specialized proresolving mediators (SPMs). In this issue, Bang et al. show that the G protein–coupled receptor GPR37 is a receptor for one such SPM, neuroprotectin D1. They also show that GPR37 activation in macrophages enhances phagocytosis, shifts cytokine release toward an antiinflammatory profile, and thereby helps to reverse inflammatory pain.

Authors

Lintao Qu, Michael J. Caterina

×

Figure 1

NPD1-GPR37 signaling promotes resolution of inflammatory pain.

Options: View larger image (or click on image) Download as PowerPoint
NPD1-GPR37 signaling promotes resolution of inflammatory pain.
(A) Biosy...
(A) Biosynthesis of neuroprotectin D1 (NPD1) from dietary docosahexaenoic acid (DHA). (B) Genetic knockout of the NPD1 receptor GPR37 prolongs pain evoked by zymosan injection without altering kinetics of immune cell trafficking or resolution of edema. (C) NPD1 and GPR37 signaling likely promotes resolution of inflammatory pain by both enhancing macrophage phagocytosis and shifting cytokine release toward an antiinflammatory profile. Onset of inflammation is at left; resolution phase is at right.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts